Related Experiment Video
Updated: Jun 4, 2025
09:42
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
7.4K
Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response.
Rashmi Tandon1, Inken Harder1, Dora Stölzl1
1Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
The Journal of Investigative Dermatology
|December 29, 2024
Summary
Tralokinumab effectively targets interleukin-13 (IL-13) in atopic dermatitis, improving skin gene expression. Long-term treatment is necessary for sustained recovery from this chronic skin condition.
Area of Science:
- Dermatology
- Immunology
- Genomics
Background:
- Atopic dermatitis involves skin barrier defects and immune overreactions, primarily driven by type 2 inflammation.
- Interleukin-13 (IL-13) is a key cytokine overexpressed in atopic dermatitis, contributing to skin dysfunction and inflammation.
Purpose of the Study:
- To investigate the impact of IL-13 inhibition with tralokinumab on the skin's transcriptome in patients with moderate-to-severe atopic dermatitis.
Main Methods:
- Prospective study involving RNA sequencing of skin biopsies from 16 patients at baseline, week 2, and week 16.
- Analysis of gene expression changes following tralokinumab treatment.
Main Results:
- Tralokinumab therapy modulated gene expression related to keratinocyte function, itch, and inflammation.
- Skin transcriptome profiles shifted from lesional toward nonlesional patterns during treatment.
- Significant gene dysregulation persisted at week 16, indicating a need for ongoing therapy.
Conclusions:
- IL-13 inhibition with tralokinumab profoundly impacts the skin transcriptome in atopic dermatitis.
- Achieving deep and sustained responses in moderate-to-severe atopic dermatitis may require long-term immunomodulatory treatment.
